The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …

BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell
maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We …

These guidelines are a consensus work of a considerable number of members of the
immunology and flow cytometry community. They provide the theory and key practical …

The introduction of novel agents has led to major improvements in clinical outcomes for
patients with multiple myeloma. To shorten evaluation times for new treatments, health …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

PURPOSE Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …